Verve Therapeutics company info

What does Verve Therapeutics do?
Verve Therapeutics (NASDAQ:VERV) is a biotechnology company focused on revolutionizing the treatment of cardiovascular diseases through gene editing. With a robust pipeline of innovative gene-editing therapies, Verve's main objective is to develop treatments that can permanently reduce the risk of coronary heart disease, the world's leading cause of death, with a single dose. The company leverages precise gene editing technologies, like CRISPR, to target the underlying genetic causes of these diseases, aiming to provide enduring therapeutic solutions. By focusing on the most common genetic contributors to cardiovascular risk, Verve aspires to transform the approach to heart disease prevention, moving from chronic management to one-time, potentially curative treatments.
Verve Therapeutics company media
Company Snapshot

Is Verve Therapeutics a public or private company?

key
Ownership
Public

How many people does Verve Therapeutics employ?

people
Employees
269

What sector is Verve Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Verve Therapeutics?

location pin
Head Office
Massachusetts, United States

What year was Verve Therapeutics founded?

founded flag
Year Founded
2018
What does Verve Therapeutics specialise in?
/Gene Editing /Cardiovascular Diseases /Therapeutic Services /Genome Medicines /Biopharmaceutical Industry /Clinical Research

What are the products and/or services of Verve Therapeutics?

Overview of Verve Therapeutics offerings
VERVE-101, designed to permanently turn off the PCSK9 gene in the liver for lowering LDL cholesterol and treating atherosclerotic cardiovascular disease.
VERVE-201, targeting ANGPTL3 gene for patients with heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease, aiming to reduce plasma lipids.
Preclinical stage programs focusing on additional genes implicated in cardiovascular disease, expanding the potential treatment options.
Gene editing technology platform, utilizing base editing to precisely target and edit specific genetic locations, potentially lowering the risk of off-target effects.
Proprietary lipid nanoparticle delivery system, developed to efficiently deliver gene editing tools to the liver, enhancing the precision and effectiveness of treatments.

Who is in the executive team of Verve Therapeutics?

Verve Therapeutics leadership team
  • Dr. Burt A. Adelman M.D.
    Dr. Burt A. Adelman M.D.
    Co-Founder & Independent Chairman of the Board
  • Dr. Sekar  Kathiresan M.D.
    Dr. Sekar Kathiresan M.D.
    Co-Founder, CEO & Director
  • Mr. Andrew D. Ashe J.D.
    Mr. Andrew D. Ashe J.D.
    President, COO & General Counsel
  • Dr. Andrew  Bellinger M.D., Ph.D.
    Dr. Andrew Bellinger M.D., Ph.D.
    Chief Scientific Officer
  • Dr. Kiran  Musunuru M.D., M.P.H., Ph.D.
    Dr. Kiran Musunuru M.D., M.P.H., Ph.D.
    Co-Founder
  • Dr. J. Keith Joung M.D., Ph.D.
    Dr. J. Keith Joung M.D., Ph.D.
    Co-Founder
  • Dr. Anthony  Philippakis M.D., Ph.D.
    Dr. Anthony Philippakis M.D., Ph.D.
    Co-Founder & Scientific Advisory Board Member
  • Dr. Barry S. Ticho FACC, M.D., Ph.D.
    Dr. Barry S. Ticho FACC, M.D., Ph.D.
    Co-Founder